Agios Pharmaceuticals Inc Virtual Investor Event to Review Data Presented at ASH Transcript
Good morning, everyone. Thank you for joining us this morning for our Agios ASH 2020 virtual investor event. I'm Jackie Fouse, the CEO and we have several members of the team with us today, who you will hear from and see in just a moment.
Let me start by flashing our forward-looking statements across the screen. There you have those.
Today, here's the agenda that we have. I have some quick opening remarks to get us started. I'll then turn it over to Chris Bowden, our Chief Medical Officer, who will talk about mitapivat, our PKR activator; AG-348 and its mechanism of action; and give you some clinical updates, including about our thalassemia pivotal trial plan. And he'll also cover the top line ACTIVATE data that we released last week. And then we'll spend the bulk of the discussion this morning with Dr. Swee Lay Thein, who will go through her slides on sickle cell disease, and we'll move into a Q&A. So thank you again for joining us.
Patients have been at the core of everything that we do at Agios since
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
